Back to Trades
Total Value
$1.8M
Net $863.6K sold
Filing Date
Jul 9, 2026
1 transaction
Sales
$863.6K
1 transaction
Trade Summary
On Jul 7, 2026, Diaz Allene M., Director, sold $1.8M of IONIS PHARMACEUTICALS INC (IONS) across 1 transaction. The filing covers Common Stock and reflects net selling of $863.6K. Reported prices ranged from $47.11 to $85.42. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- IONIS PHARMACEUTICALS INC
- Ticker Symbol
- IONS
- CIK
- 0000874015
Insider Information
- Name
- Diaz Allene M.
- Role
- Director
- Location
- CARLSBAD, CA
Filing Details
- Filing Date
- Jul 9, 2026
- Transaction Date
- Jul 7, 2026
- Accession Number
- 0000874015-26-000237
- Form Type
- 4
- Net Trading Amount
- -$863.6K
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 7, 2026 | Common Stock | 10,111 | $47.11 | Exercise | $476.3K |
| Jul 7, 2026 | Common Stock | 10,111 | $85.42 | Sale | $863.6K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 7, 2026 | IONS derivative | 10,111 | $47.11 | Exercise | $476.3K |
Want live alerts when Diaz Allene M. trades again?
Download Insider Trades to track IONS, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025.
- (F2)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.040 to $85.730 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.